English

Choose language

Back

  • Deutsch

  • ελληνική

  • English

  • Español

  • Français

  • Polski

  • Português

  • Русский

  • Українська


English

How do you prefer to top up your account?

* We don't charge any commission for making deposits into your account

Novartis International

13.73%
Growth potential
88 USD
Price per share
USD
3.63%
Dividend income
Novartis International sold by lots comprising 1 pc.
Enter the number of securities
Order price:
Brokerage commission:
Transfer commission:
Caring and curing
Why invest in Novartis International?
  • The second largest pharma company
  • The second medical drug producer in Europe by market share
  • Number 52 in Forbes Global 2000
  • Over €178B market cap as of now


1d
1w
1mo
6mths
All the time
Recommendations of the largest investment banks
Berenberg
Buy
29.09.2020
UBS
Buy
10.09.2020
Morgan Stanley
Buy
01.09.2020
Citigroup
Buy
15.06.2020
Financial indicators
Capitalization
211.19B USD
P / E
16.04
Profit
52.59B USD
Net profit
33.18B USD
The general recommendation of investment banks

Buy

Based on the analytics from 6 of the world's largest investment banks over the past 3 months

Forecasted prices

Target price

102 USD

(16.8% Growth potential)

Based on the data from 6 of the leading investment banks

Novartis International AG is a Swiss multinational pharmaceutical company headquartering in Basle (Switzerland). It is one of the major pharmaceutical companies by market capitalization and sales. Novartis is engaged in the production of such medications as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), Imatinib mesylate (Gleevec), cyclosporine (Neoral / Sandimmun), Letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), etc. In 1996, Ciba-Geigy consolidated with Sandoz; pharmaceutical and agrochemical sectors of both companies have formed an independent entity of Novartis. Other Ciba-Geigy and Sandoz businesses were sold or like Ciba Specialty Chemicals made independent entities. The Sandoz brand withdrew from the market in three years, but it got back in 2003 when Novartis integrated its generic producing business into an affiliated company under the title Sandoz. Novartis is a full-fledged member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) as well as The Pharmaceutical Research and Manufacturers of America (PhRMA).

Not all companies have really great missions. Medtronic, however, does have it: it is striving to help sick people recover and live better. Medtronic, based in the US, is a global leading company in developing and producing medical technologies, devices, and equipment used by millions of people throughout the world. The company has 44 factories and 25 research centers across the globe. Its 45,000 employees are working on a daily basis to improve the current treatment methods and create new ones. Since its inception, Medtronic created over 150,000 various products that help to treat over 50 chronic diseases. The experts report that around 6 to 7 million lives are saved yearly thanks to Medtronic's technologies and equipment.

Receive ideas for profitable investments - faster than the market

We will be sending you a letter once a week with the most relevant information

Congratulations!

Now you will always be aware of which stocks are more profitable to invest in